abstract: After four decades of study, the biological role of fetal microchimerism (FMC) remains elusive. Transfer of fetal cells to the mother begins soon after implantation, and increases with gestational age. FMC cells then decline after delivery, but remain detectable for years post-partum. These cells have been implicated in rheumatoid arthritis remission during pregnancy and the prevention of breast cancer by graft-versus-tumor-effects. However, any beneficial effects contrast with their suspected malevolence in triggering of systemic sclerosis after childrearing or their stromal support for tumor formation. Recent evidence that FMC cells participate in disease and tissue repair has stirred controversy on their origin. The detection of FMC cells during early embryogenesis together with the diversity of hematopoietic, mesenchymal and endothelial markers, and plasticity of morphology when integrated into various tissues, provides evidence for their stemness. However, proof of their phenotype in conventional stem cell differentiation assays has been beset with difficulty in isolating and expanding them in culture. Unraveling the function of FMC cells will provide insight into both their engagement in disease and their therapeutic potential.
Introduction
Microchimerism is defined as the presence of small amounts of foreign DNA in a genetically different individual. Although fetal microchimerism (FMC) or the transfer of fetal cells to the mother occurs naturally during all pregnancies, we are only beginning to understand its implications. FMC was first recognized as a natural phenomenon in pregnant women in the early 1970s using the laborious approach of visual analysis of lymphocyte mitoses cultured from maternal blood to identify infrequent fetal cells followed by karyotyping for confirmation (Walknowska et al., 1969; Anderson and Ferguson-Smith, 1971; Schindler and Martin-du-Pan, 1972) . Since then, using more sensitive methods, fetal cells have been consistently observed in healthy parous women (Covone et al., 1984; Bianchi et al., 1990; Chua et al., 1991) , remarkably for decades after delivery (Bianchi et al., 1996) . Despite years of research since 1969, the biological consequences of FMC remain elusive. Recent observation of their involvement in autoimmune diseases and cancer raises questions of whether they are the instigators of diseases or just natural reparative cells.
FMC detection
Polymerase chain reaction (PCR) detects male fetal cell Y chromosome sequences in the maternal circulation, whereas interphase FISH enables direct visualization of the Y chromosome in individual cells to complement immunohistochemistry on tissue sections. Amplification of target nucleic acid during PCR reliably detects and quantifies Y chromosome sequences among a background of maternal DNA with an average sensitivity of 1 male among 10 5 maternal cells (Yan et al., 2005) . Although the Y chromosome is the only 'universal' marker of FMC, it is only applicable to tracking half the FMC cells and does not distinguish between the contributions from different male fetuses. Surprisingly, even nulliparous women have been shown to host low quantity of Y chromosome DNA (Yan et al., 2005) , presumably due to resorbed pregnancies, but possibly also from an unborn twin brother (Sato et al., 2008) or perhaps an elder brother through their mother (Guettier et al., 2005) . An alternative approach applicable to both sexes is the detection of non-shared HLA polymorphisms among family members, albeit at a poorer sensitivity of 5 fetal among 10 5 maternal cells (Tokita et al., 2001; Lambert et al., 2004) . As human studies are handicapped by the imprecision of retrospective pregnancy history and the difficulty in accessing living tissues, murine models have added substantially to our understanding of FMC. Despite slight differences such as the labyrinthine nature of murine placentation, anatomical observation and gene expression studies suggest that the human and murine placenta share largely analogous functions (Georgiades et al., 2002) . Genetically modified mice with a reporter gene enable us to track FMC cells from the fetus to the mother. Exogenous markers such as T6 (Liegeois et al., 1981) and green fluorescent protein (gfp) are examples of fetal tags for straightforward detection in maternal tissue. By mating a wild-type female mouse to a male transgenic for gfp, fetal gfp+ cells in the mother can be differentiated from maternal ones (Khosrotehrani et al., 2005a; Fujiki et al., 2009) . ROSA26-gfp knock-in mice (Kisseberth et al., 1999; Fujiki et al., 2008) express gfp uniformly at the ROSA26 locus of each cell, providing an additional means to quantify FMC cell number by direct visualization of histological sections. More recently, we have used the expression of cell lineage promoters such as fibroblast-specific Col 1a2 (Fig. 1) or endothelial-specific VEGFR2 (Nguyen Huu et al., 2007) in transgenic mice to define not only the presence of the FMC but also their function. The Cre-lox system has added yet another dimension through its ability to switch on the transgene at a desired time point. Conditional expression in response to a drug such as tamoxifen in double transgenic models should provide a great potential resource for future tracking and identification of FMC (Feil et al., 2009 ).
Origin and persistence of FMC
FMC was initially considered a simple phenomenon of cellular exchange between maternal and fetal circulations across the placental barrier. However, trafficking of fetal cells to the maternal spleen, liver, kidney, pancreas, heart, lung and bone marrow occurs as early as Day 6-7 of murine gestation (Khosrotehrani et al., 2005a; Sunami et al., 2010) , when the placental circulation has not yet developed. FMC cell numbers continue to increase with gestational age (Fujiki et al., 2009 ) either due to continuous migration of cells across the placenta or proliferation of cells that migrated before Day 6.
In human pregnancy, fetal cells are observed from 6 to 7 weeks of gestation, numbers increasing thereafter with gestational age (Pertl and Bianchi, 1999; Ariga et al., 2001) . Fetal cells in the maternal circulation are now considered a ubiquitous phenomenon, their frequency estimated at 2 -6 cells per ml of blood in normal second trimester pregnancy (Krabchi et al., 2001) . They were believed to persist for only 1 month after delivery (Hamada et al., 1995) , but recent results show that they can be found in the circulation of 23 -64% of healthy parous women years or decades after pregnancy (Bianchi et al., 1996; Evans et al., 1999; Kirschstein and Skirboll, 2001; Artlett et al., 2002; Lambert et al., 2002; Gilmore et al., 2008) .
Pregnancy disorders are associated with increased frequency of circulating FMC, most likely due to placental dysfunction with increased trophoblast shedding and fetomaternal hemorrhage, as observed in fetal aneuploidy (110 versus 19 per 16 ml in normal pregnancy) (Bianchi et al., 1997) and pre-eclampsia (7 versus 2 per 2000 cells in normal pregnancy) (Chua et al., 1991; Holzgreve et al., 1998) . A history of bearing male children is not associated with persisting FMC but fetal loss is ; Khosrotehrani et al., Figure 1 In vivo tracking of FMC cells by bioluminescence. Further to our recent report (Nguyen Huu et al., 2007) showing the utility of bioluminescence for FMC tracking, these unpublished images show wild-type C57BL/6 (B6) female mice bred to males transgenic for luciferase driven by the Col1a2 promoter. The resulting embryos and fetal cells were luminescent when Collagen Type I is expressed. At E10, the abdominal region of a pregnant female is luminescent due to the collagen-expressing embryos but not the region circled in red where a punch biopsy was freshly made. Seven days after the biopsy (E17), the site showed luciferase activity due to the transfer of collagen-expressing fetal cells that are participating in tissue repair. At 2 weeks post-partum (P14), tissue repair was completed as suggested by the lack of luciferase activity. Instead, luciferase activity is seen at a second biopsy site that was created at P7 and indicated by the white square.
2003) as confirmed in a murine model (Johnson et al., 2010) , and induced abortion results in greater frequency of FMC than spontaneous miscarriage (Yan et al., 2005) .
FMC and autoimmune disease
The presence of maternal antibodies against fetal major histocompatibility complex (MHC) proteins indicates the mother's awareness of the foreign antigens, yet curiously the fetus is not rejected. The postpartum onset of systemic sclerosis (SSc) in women bearing MHC-similar children (Nelson et al., 1998) suggests that FMC immune cells might attack maternal tissue while escaping immune surveillance, potentially leading to autoimmune diseases (Nelson, 1996) . Compared with healthy women, FMC cells were found in higher numbers and sometimes frequency in the skin (Sawaya et al., 2004) , salivary glands (Aractingi et al., 2002) and circulation (Artlett et al., 1998; Nelson et al., 1998) of SSc patients, and were more alloreactive toward maternal MHC in culture (Scaletti et al., 2002) . It is notable that unaffected skin of SSc patients has more FMC cells than lesional skin but fewer inflammatory cells, while the converse is true for nonlesional skin, suggesting that the FMC cells were initiating inflammatory events (Sawaya et al., 2004) . However, similar frequencies of FMC have been found in the peripheral blood of SSc and healthy women (Murata et al., 1999; Ichikawa et al., 2001; Gannagé et al., 2002; Selva-O'Callaghan et al., 2003) .
The participation of FMC cells in other autoimmune diseases remains undetermined. They can be found in the salivary glands of Sjö gren's syndrome (SS) patients but their involvement in the pathology of SS is uncertain (Toda et al., 2001; Endo et al., 2002; Kuroki et al., 2002) . Investigation of FMC in systemic lupus erythematosus (Miyashita et al., 2000; Ohtsuka et al., 2001; Abbud Filho et al., 2002; Khosrotehrani et al., 2005b; Kremer Hovinga et al., 2007) and autoimmune thyroid diseases (Klintschar et al., 2001; Srivatsa et al., 2001; Ando and Davies, 2003; Pedersen et al., 2006) has also yielded mixed results. Interestingly, FMC cells were significantly higher than controls in a lupus nephritis model, suggesting that more severe tissue damage might be required for cells to be observed (Khosrotehrani et al., 2005b; Mosca et al., 2009) . Thus, participation of FMC cells in autoimmune diseases depends on factors such as cell phenotype and MHC compatibility. However, conflicting evidence has obscured delineation of their role (Klonisch and Drouin, 2009; Nelson, 2009) . Their engraftment in pre-lesional skin seems to favor a triggering role in the immune response, but their presence in lesions may be related to tissue repair. The identification of fetal mesenchymal stem cells (MSC) in the maternal circulation (O' Donoghue et al., 2003) adds to the complexity of their immunological interplay with maternal cells or even among FMC cells, as MSC are known to exert immunosuppressive effects (Ringden et al., 2006) .
FMC and cancer
Patients with cancer have a reduced frequency of circulating fetal cells compared with healthy women, yet a higher frequency at tumor sites compared with unaffected tissue (Table I ). The occurrence of circulating fetal cells is 2-4 times lower, found in 11 -26% of breast cancer patients compared with 48-56% of healthy parous women (Gadi and Nelson, 2007; Gadi et al., 2008) . When other solid tumors are considered, circulating FMC in healthy parous controls is still twice as frequent compared with patients (57 versus 28%) (Gilmore et al., 2008) . These observations raise the question of whether lower FMC frequency is a cause of cancer due to a deficit in protection by FMC cells. Alternatively, these observations could simply result from cellular recruitment to the tumor and thus depletion of FMC cells from the circulation.
Fetal cells have been found in up to half of papillary thyroid tumors (Srivatsa et al., 2001; Renne et al., 2004; Cirello et al., 2008) , more frequently in breast and skin cancer tissue (Fig. 2) (Dubernard et al., 2008 Nguyen Huu et al., 2009 ) and all cervical cancer tissue . However, information on their phenotype in maternal cancer tissue is limited. In cervical cancer, up to half the fetal cells were positive for either CD45 or cytokeratin markers, but not both . In breast cancer, fetal cells mainly possess epithelial markers, with some mesenchymal but not leukocyte determinants, suggesting FMC cells contribute to tumor stroma via mesenchymal-epithelial transition (Dubernard et al., 2008 .
The mechanism underlying the apparent protective effect of FMC is unknown, but alloreactivity between FMC and maternal cells offers some clues. The rejection of FMC cells by maternal immune cells is evident from the lower frequency of FMC after allogenic compared with congenic matings in mice (Bonney and Matzinger, 1997; Khosrotehrani et al., 2005a) . The converse may be true in that FMC cells comprising leukocytes are capable of mounting an immune response against genetically different malignant maternal tissue in the phenomenon known as graft-versus-tumor (GVT) effect (Gadi, 2009) . In fact, it has been proposed that genetically distinct chimeric cells in the context of bone marrow transplantation provide better surveillance, recognition and cytotoxicity effect against tumor cells compared with maternal immune cells. This is supported by fewer relapses resulting from the mismatch in minor histocompatibility antigens between the leukemia recipient and the hemopoietic stem cells (HSC) donor (Horowitz et al., 1990) .
Based on current understanding of bone marrow transplantation immunology among family members, three potential mechanisms for GVT by FMC cells have been postulated (Gadi, 2009) The apparent benefit of FMC in cancer prevention, however, is not consistent with the observation that fetal cells of mesenchymal origin can integrate in the tumor stroma (Dubernard et al., 2008) . Indeed, recent work localizing MSC to breast carcinoma has associated them with cancer stromal support and metastasis (Karnoub et al., 2007) , and higher FMC cell number was associated with high-grade breast tumors . In a murine model, FMC cells participated in lymphangiogenesis, again suggesting they might facilitate metastasis (Nguyen Huu et al., 2009) . To date, fetal-derived entire tumors have not been reported in humans, with the exception of a report in one animal of lung tumors of apparently fetal origin (Sawicki, 2008) . Nevertheless, the growing evidence in the cancer field of rare cancer stem cells that do not respond to chemotherapy and escape immune surveillance raises questions on the involvement of FMC cells in cancer (Frank et al., 2010) . It remains to be seen whether pregnancy protects against cancer or increases its frequency.
Stemness of FMC cells
Phenotyping of FMC cells in maternal circulation and tissue has identified a variety of cell types. Observed FMC cell types in the circulation include trophoblasts, T or B lymphocytes, monocytes, NK cells and CD34+ cells (Bianchi et al., 1996; Evans et al., 1999; Khosrotehrani et al., 2008; Fujiki et al., 2009) . In tissue, FMC cells have been shown in situ to be hepatocytes (Johnson et al., 2002; Khosrotehrani et al., 2004; Stevens et al., 2004; Wang et al., 2004; Guettier et al., 2005) , kidney tubular epithelium (Wang et al., 2004) , neurons and glia (Tan et al., 2005) , cardiomyocytes (Bayes-Genis et al., 2005) , endothelial cells, thyrocytes (Srivatsa et al., 2001; Khosrotehrani et al., 2004; Cirello et al., 2010) and intestinal epithelium (Khosrotehrani et al., 2004) . Differentiated FMC cells in maternal tissue have been postulated to arise from lymphoid progenitors (Bianchi et al., 1996; Khosrotehrani et al., 2008) , MSC (O'Donoghue et al., 2003) and endothelial progenitor cells (EPC) (Parant et al., 2009) . The stemness of originating FMC cells is supported by the diversity of phenotypes displayed (Khosrotehrani et al., 2004; Fujiki et al., 2009 ) and the maternal tissues in which they integrate (Sunami et al., 2010) . As both primitive and mature cell types have been identified, FMC cells are either stem/progenitor cells that differentiate into cell types of the microenvironment in which they reside, or cells that adopt specific lineages prior to their transplacental passage. Current evidence points to the transfer of stem cells during early pregnancy. FMC cells detected in mouse maternal circulation from E6-7 embryos (Khosrotehrani et al., 2005a; Sunami et al., 2010) arose from cells of the trophoblast, primitive endoderm or epiblast that could have migrated to the maternal circulation any time after implantation. This putative state of migratory cells potentially puts them on the same level of pluripotency as embryonic stem cells derived from the inner cell mass or they could just be trophoblast, but their ability to adopt the morphology of various surrounding phenotypes argues for the former. This suggests that the early migratory FMC cells may have greater differentiation potential than MSC, HSC or EPC. Cross-sectional studies using hysterectomy performed at intervals between gestational Days 4 and 7 will help clarify the gestational ontogeny of resultant FMC cells (Sunami et al., 2010) .
The significance of microchimeric cell stemness is the potential for natural stem cell therapy as a result of pregnancy. The defining properties of a stem cell include virtually unlimited expansion (selfrenewal), expression of a specific set of markers, and ability to give rise to all mature cells of a specific lineage with a variable degree of plasticity (multi or pluripotency) (Domen and Weissman, 1999) . There have been few attempts to validate the stemness of FMC cells by in vitro differentiation assays or in vivo repopulation assays. For example, HSC should generate human B-and T-lymphoid and myelo-erythroid cells in an irradiated host (Traggiai et al., 2004) . Instead, HSC have been considered to be among FMC cells based largely on evidence of CD34 marker expression. More fetal cells were found if circulating mononuclear cells of previously pregnant women were preselected for CD34+ (Bianchi et al., 1996; Adams et al., 2003; Mikhail et al., 2008) . Low-level FMC was found among a third to half of white cell subsets in healthy and scleroderma patients (Evans et al., 1999) , similar to observations in rhesus monkeys (Jimenez et al., 2005) , suggesting they arise from microchimeric HSC. Direct evidence of microchimeric lymphoid progenitors comes from the observation of CD4+8+ immature lymphocytes in the thymus of immune-deficient RAG mice mated to immunocompetent males. Such cells differentiate into functional T cells and thus provide evidence for the transfer of a microchimeric lymphoid progenitor .
Fetal MSC have also been identified in the maternal circulation (O'Donoghue et al., 2003) . Fetal MSC, believed to arise from the aorta-gonad-mesonephros region during embryogenesis (Van Den Heuvel et al., 1987) , enter the fetal circulation from 7 weeks of gestation but decline to insignificant numbers by week 14 (Campagnoli et al., 2001) . As 'tri-lineage' differentiation into bone, fat and cartilage is a hallmark of MSC (Pittenger et al., 1999) , microchimeric fetal MSC are a potential source for stem cell repair in diseases such as osteogenesis imperfecta (Le Blanc et al., 2005; Guillot et al., 2008a) . Fetal MSC have been found in the maternal bone marrow, isolated in culture and shown to have tri-lineage capacity (O'Donoghue et al., 2004) . To date, this is the only instance where stemness has been shown in fetal cells isolated from maternal tissues.
Thus most evidence suggesting stemness of FMC cells is indirect and originates from observations of fetal cell phenotype in different tissues. The observation of male cells positive for CD3 and desmin at the maternal appendix hints at FMC cells of hematopoietic and mesenchymal origin respectively participating in tissue repair (Santos et al., 2008) . Demonstration of fetus-derived blood vessels in maternal inflammation or melanoma (Nguyen Huu et al., 2007 ) suggests angiogenic activity of endothelial progenitor cells. Indeed, most CD34+ cells in the intervillous space and in the maternal placental Fetal stem cell microchimerism blood are endothelial and of fetal origin at term (Parant et al., 2009) , and express CD34, CD31 or von Willebrand factor endothelial markers.
Fetal stem cell therapy
Since fetal stem cells are available in maternal blood during pregnancy and possess superior plasticity, they could represent a promising cell source for ex vivo manipulation and autologous therapy, including in utero. However, the isolation and expansion of rare-event FMC cells while maintaining fetal cell stemness present a major technological challenge due to their infrequency. Umbilical cord blood has been hyped to be an ideal autologous source of stem cells for post-natal transplantation. This may represent a viable strategy for hematopoietic stem cell transplantation but MSC isolation is limited to fewer than half of cord samples (Campagnoli et al., 2001; Rebelatto et al., 2008) . A more abundant source of therapeutic cells, albeit not for autologous use, is fetal tissue from pregnancy terminations from which HSC (Baum et al., 1992) , neural stem cells (Brustle et al., 1998) , MSC (Campagnoli et al., 2001) and EPC (Ingram et al., 2005) can be generated. Similarly, by-products of term delivery such as amniotic fluid (Parolini et al., 2009) , placental tissue (Castrechini et al., 2010; Portmann-Lanz et al., 2010) and the umbilical cord (Weiss and Troyer, 2006) while harboring less differentiation potential than fetal tissue, will continue to generate interest as abundant and ethically uncomplicated sources. First-trimester MSC and possibly other cell types can also be generated from chorionic villus biopsy tissue, suitable for autologous applications (Portmann-Lanz et al., 2006) .
Fetal stem cells offer considerable therapeutic potential compared with their adult counterparts as they are more primitive. For example, fetal MSC have longer telomeres, express embryonic pluripotency markers such as Nanog and Oct4 (Guillot et al., 2007) , possess superior osteogenic potential (Guillot et al., 2008b; Zhang et al., 2009 ) and capacity to differentiate beyond conventional lineages (Chan et al., 2006; Kennea et al., 2009) . Fetal MSC have been identified in hemopoietic (Campagnoli et al., 2000 (Campagnoli et al., , 2001 and numerous other fetal organs (Almeida-Porada et al., 2002; Hu et al., 2003; Rzhaninova et al., 2005; Zhao et al., 2005) . Just as fetal cells have been shown to cluster at sites of pathology in acquired maternal disease, it is possible they may also contribute in genetic diseases in the mother for which stem cell therapy is being developed in affected fetuses, such as some muscular dystrophies, skeletal dysplasias, and inborn errors associated with survival into adulthood.
Future FMC studies
Quantification of FMC cells in normal or lesional tissue from both healthy and diseased individuals will remain a mainstream priority for FMC research. Serial sampling of post-reproductive blood will facilitate the study of the association between FMC frequency and diseases. Detection of non-shared HLA will be useful in quantifying the contribution of FMC from different children including daughters, but its sensitivity has yet to match the detection of Y chromosome DNA (Lambert et al., 2004; Saraji et al., 2007) .
In animal models, improvements in in vivo imaging are needed to improve sensitivity and/or resolution to offer robust detection of FMC cells. Bioluminescent imaging currently offers high specificity but low depth of penetration. Advances in contrast agents which show promise for in vivo FMC cellular tracking include new nanoparticle formulations (Lee et al., 2010) which provide improved contrast and longitudinal tracking of EPC or MSC by magnetic resonance imaging (Lee et al., 2009) .
For FMC to become a multipotent cell source for therapeutic application, isolation of a self-renewal FMC from maternal circulation will be challenging. An alternative would be sampling maternal tissue noninvasively to obtain expandable FMC cells. An intentional superficial wound may generate local cellular proliferation to enable subsequent enrichment of a stable FMC cell line, which might also provide sufficient FMC cells for non-invasive prenatal diagnosis. Insight into the true reparative effects of FMC cells may be gained in women with genetic diseases from the study of the regenerative effects of pregnancy with unaffected fetuses.
Conclusion
Improvement in FMC detection and eventual isolation may elucidate the phenotype of FMC cells at each stage of gestation, and lend new insights into the migration of pluripotent/multipotent cells during embryogenesis and transplacental passage. Further studies of FMC cells in autoimmunity and cancer in both patients and animal models will yield further information on their role in disease prevention or progression. Whether FMC cells are natural-born healers or killers remains unknown, but with further elucidation of this phenomenon, we hope one day both to avoid the damage they may bring, or indeed, harness their therapeutic potential.
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